Immunome, Inc.
IMNM
Positions held
Your positionsIMNM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Immunome, Inc. operates in the biotechnology sector, focusing on innovative therapeutic solutions, which positions it well for future growth as the demand for advanced healthcare solutions increases.
- The company has a market cap of approximately $2.28 billion, indicating significant investor interest and potential for growth.
- Analysts have given a strong buy recommendation for IMNM, with a target mean price of $35.2.
- Immunome, Inc. faces significant financial challenges, including a negative profit margin and operating margin, which raises concerns about its sustainability.
- In 2025, the company reported a net income loss of $212.394 million, reflecting ongoing financial struggles.
- The stock has a strong sell signal with a score of -16.00, indicating bearish market sentiment and unfavorable technical indicators.
Fundamentals
| Market cap | $2.28B | Enterprise value | $1.68B | Trailing P/E | — | Forward P/E | -7.96 |
| PEG | — | Price / book | 4.17 | Beta | 2.56 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -64.0% | ROA | -37.8% | Debt / equity | 0.01 |
| Current ratio | 15.08 | Free cash flow | -$143.66M | Analyst recommendation | strong_buy | Mean target | $35.20 |
| 52w high | $30.06 | 52w low | $13.49 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $4.0M | — |
| Op margin | — | — | — | — | -1157.6% | — |
| Net income | -$73.1M | -$53.8M | -$69.9M | -$57.5M | -$43.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$78.1M | -$59.3M | -$72.9M | -$60.1M | -$46.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | $0.0M | — |
| Op margin | -3228.8% | -1697.3% | -204.9% | — | — |
| Net income | -$212M | -$293M | -$107M | -$36.9M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$224M | -$153M | -$28.7M | -$36.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 · Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
2026-10-01 · Stifel Initiates Immunome at Hold With $24 Price Target
2026-10-01 · Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues
2026-09-30 · Immunome Gets FDA Clearance for IM-1340 Clinical Trial in Advanced Solid Tumors
2026-09-08 · Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-12 · Wedbush Adjusts Price Target on Immunome to $35 From $31, Keeps Outperform Rating
2026-08-11 · Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 · Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns